Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 612, S48-S49 (2022)
doi: https://doi.org/10.1038/d41586-022-04343-7
This article is part of Nature Outlook: Children‘s health, an editorially independent supplement produced with the financial support of third parties. About this content.
Updates & Corrections
-
Correction 19 January 2023: This Outlook article misrepresented the results of ref. 3. The 60% efficacy of the protection of the combination of RTS,S with chemoprevention was relative to either intervention on its own, not the efficacy of the combination itself.
References
RTS,S Clinical Trials Partnership. Lancet 386, 31–45 (2015).
Hogan, A. B., Winskill, P. & Ghani, A. C. PLoS Med. 17, e1003377 (2020).
Chandramohan, D. et al. N. Engl. J. Med. 385, 1005–1017 (2021).
Datoo, M. S. et al. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(22)00442-X (2022).